
    
      The duration of the study for an individual patient will include a period to assess
      eligibility of up to 4 weeks, a treatment period of at least 6 weeks of study treatment, and
      an end-of-study visit at least 30 days (or until the patient receives another anti-cancer
      therapy, whichever is shorter) following the last administration of study drug.
    
  